Developer docs
API playgroundTry for free, no card

Search company profiles

CellforCure

Full company profile

uuid003bifa

Namestring
CellforCure
Legal namestring
CELLforCURE
Websiteurl
cellforcure.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, gene therapy CDMO, advanced therapy medicinal products, GMP biopharmaceutical services, contract development manufacturing
Industry4 codes
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical CDMO Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1CDMO Manufacturing Services
TypeManaged Services
Description

CELLforCURE generates revenue through contract development and manufacturing services for biotech companies developing cell and gene therapies. As a CDMO, the company provides GMP manufacturing capacity and expertise on a project-by-project basis, serving as a strategic manufacturing partner for therapy developers from clinical through commercial stages.

bioprocessintl.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

CELLforCURE is a contract development and manufacturing organization (CDMO) providing GMP-certified manufacturing of Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies. The company operates a 10,000 m² one-stop-shop facility in France with 3,000 m² of EMA-authorized, FDA-compliant GMP cleanroom space, supporting therapy developers from early-stage development through Phase III clinical trials to commercial launch.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CELLforCURE, part of the France-based SEQENS Group, operates as a contract development and manufacturing organization (CDMO) specializing in GMP manufacturing of advanced therapy medicinal products (ATMPs). The company provides a one-stop-shop manufacturing platform offering integrated GMP manufacturing space across its EMA-authorized, FDA-compliant facility in France. CELLforCURE's core service encompasses cell therapy manufacturing and support for therapy developers in scaling from early-stage development through clinical trials to commercial launch.

Product and service1 record
1CELLforCURE GMP Manufacturing Services
CategoryBiopharmaceutical CDMO Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1BBG Advanced Therapies (BioBridge Global)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-08
Description

BBG Advanced Therapies, a subsidiary of BioBridge Global based in San Antonio, Texas, partnered with CELLforCURE to create a transatlantic manufacturing network for ATMPs. The collaboration combines BBG's 9 cGMP cleanrooms in Texas with CELLforCURE's European GMP facilities, enabling U.S. companies to access European manufacturing and vice versa. This partnership supports therapy developers scaling from early-stage development through multinational clinical trials to commercial launch.

finance.yahoo.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CellProthera partnered with CELLforCURE as its CDMO for Phase III manufacturing and commercialization of the ProtheraCytes cell therapy. CELLforCURE provides GMP manufacturing services to support the pivotal Phase 3 trial in the USA and Europe for the stem cell therapy targeting ischemic heart disease.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Yposkesi
TypeDirect peer
Description

Yposkesi is a France-based CDMO specializing in cell and gene therapy GMP manufacturing, located near Paris. It is the most direct European peer to CellforCure, competing for the same ATMP developers with overlapping regulatory credentials (EMA/FDA) and similar scale.

TypeRegional player
Description

RoslinCT is a UK-based cell therapy CDMO offering GMP manufacturing for cell and gene therapies. It is a regional peer to CellforCure with comparable scale and a similar focus on clinical and commercial ATMP manufacturing, primarily serving European clients.

TypeBroad incumbent
Description

AGC Biologics is a global CDMO offering cell and gene therapy, viral vector, and biologics manufacturing services. It is comparable as a multi-modality CDMO with growing ATMP capacity competing for cell therapy manufacturing contracts, with broader modality coverage than CellforCure.

TypeEmerging player
Description

Center for Breakthrough Medicines is a US-based cell, gene, and biologics CDMO offering GMP manufacturing services. It competes for the same ATMP developers as CellforCure, particularly given CellforCure's transatlantic ambitions through the BBG partnership.

TypeEmerging player
Description

CellGenix supplies GMP-grade raw materials and also offers development and manufacturing services for cell and gene therapy. It overlaps with CellforCure in serving ATMP developers, though it is more focused on raw materials and ancillary services than full-scale cell therapy manufacturing.

TypeBroad incumbent
Description

Lonza is a global CDMO leader with a dedicated cell and gene therapy manufacturing business offering GMP manufacturing, process development, and commercial supply. It is comparable as a large incumbent competing directly with CellforCure for ATMP manufacturing contracts, but at significantly greater scale and geographic reach.

TypeEmerging player
Description

BioElpida is a European cell therapy CDMO offering GMP manufacturing for cell-based therapies, including ATMPs. It is a regional, niche competitor to CellforCure serving a similar European biotech customer base.

8GenIbet (currently Genezen)
TypeDirect peer
Description

GenIbet/Genezen is a specialized viral vector and cell therapy CDMO offering GMP manufacturing for gene-modified cell therapies. It is comparable as a niche cell-therapy-focused CDMO targeting the same biotech customer base as CellforCure.

TypeBroad incumbent
Description

Catalent's cell and gene therapy services (including the MaSTherCell acquisition) provide viral vector and cell therapy CDMO capabilities to biotech developers. It is comparable as a multi-modality CDMO serving the same ATMP customer base as CellforCure, though it is a much larger, diversified organization.

TypeBroad incumbent
Description

Through the Brammer Bio acquisition, Thermo Fisher provides viral vector and gene therapy CDMO services. It is a broad incumbent serving overlapping cell and gene therapy developers with substantially larger resources than CellforCure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CellforCure

Biopharmaceutical CDMO Servicescellforcure.com

CellforCure firmographics

Firmographics
Name
CellforCure
Legal name
CELLforCURE
Website
https://cellforcure.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

CellforCure industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell therapy manufacturing
  • Gene therapy CDMO
  • Advanced therapy medicinal products
  • GMP biopharmaceutical services
  • Contract development manufacturing

Where CellforCure is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

CellforCure business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. CDMO Manufacturing Services: CELLforCURE generates revenue through contract development and manufacturing services for biotech companies developing cell and gene therapies. As a CDMO, the company provides GMP manufacturing capacity and expertise on a project-by-project basis, serving as a strategic manufacturing partner for therapy developers from clinical through commercial stages.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

CellforCure product offering

Product offering

Core offering

CELLforCURE is a contract development and manufacturing organization (CDMO) providing GMP-certified manufacturing of Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies. The company operates a 10,000 m² one-stop-shop facility in France with 3,000 m² of EMA-authorized, FDA-compliant GMP cleanroom space, supporting therapy developers from early-stage development through Phase III clinical trials to commercial launch.

Product overview

CELLforCURE, part of the France-based SEQENS Group, operates as a contract development and manufacturing organization (CDMO) specializing in GMP manufacturing of advanced therapy medicinal products (ATMPs). The company provides a one-stop-shop manufacturing platform offering integrated GMP manufacturing space across its EMA-authorized, FDA-compliant facility in France. CELLforCURE's core service encompasses cell therapy manufacturing and support for therapy developers in scaling from early-stage development through clinical trials to commercial launch.

Differentiator

Problem solved

Functional benefit

Products and services

  • CELLforCURE GMP Manufacturing Services

Companies that use CellforCure

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

CellforCure technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

CellforCure partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BBG Advanced Therapies (BioBridge Global)coreStrategic or Co-development Partner · 8 October 2025BBG Advanced Therapies, a subsidiary of BioBridge Global based in San Antonio, Texas, partnered with CELLforCURE to create a transatlantic manufacturing network for ATMPs. The collaboration combines BBG's 9 cGMP cleanrooms in Texas with CELLforCURE's European GMP facilities, enabling U.S. companies to access European manufacturing and vice versa. This partnership supports therapy developers scaling from early-stage development through multinational clinical trials to commercial launch.
  • CellProtheracoreStrategic or Co-development PartnerCellProthera partnered with CELLforCURE as its CDMO for Phase III manufacturing and commercialization of the ProtheraCytes cell therapy. CELLforCURE provides GMP manufacturing services to support the pivotal Phase 3 trial in the USA and Europe for the stem cell therapy targeting ischemic heart disease.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

CellforCure competitors and assessment

Company assessment

Direct peers

  • Yposkesi: Yposkesi is a France-based CDMO specializing in cell and gene therapy GMP manufacturing, located near Paris. It is the most direct European peer to CellforCure, competing for the same ATMP developers with overlapping regulatory credentials (EMA/FDA) and similar scale.
  • GenIbet (currently Genezen): GenIbet/Genezen is a specialized viral vector and cell therapy CDMO offering GMP manufacturing for gene-modified cell therapies. It is comparable as a niche cell-therapy-focused CDMO targeting the same biotech customer base as CellforCure.

Regional players

  • RoslinCT: RoslinCT is a UK-based cell therapy CDMO offering GMP manufacturing for cell and gene therapies. It is a regional peer to CellforCure with comparable scale and a similar focus on clinical and commercial ATMP manufacturing, primarily serving European clients.

Broad incumbents

  • AGC Biologics: AGC Biologics is a global CDMO offering cell and gene therapy, viral vector, and biologics manufacturing services. It is comparable as a multi-modality CDMO with growing ATMP capacity competing for cell therapy manufacturing contracts, with broader modality coverage than CellforCure.
  • Lonza Cell & Gene Technologies: Lonza is a global CDMO leader with a dedicated cell and gene therapy manufacturing business offering GMP manufacturing, process development, and commercial supply. It is comparable as a large incumbent competing directly with CellforCure for ATMP manufacturing contracts, but at significantly greater scale and geographic reach.
  • Catalent (Paragon Gene Therapy / MaSTherCell): Catalent's cell and gene therapy services (including the MaSTherCell acquisition) provide viral vector and cell therapy CDMO capabilities to biotech developers. It is comparable as a multi-modality CDMO serving the same ATMP customer base as CellforCure, though it is a much larger, diversified organization.
  • Thermo Fisher Scientific (Brammer Bio): Through the Brammer Bio acquisition, Thermo Fisher provides viral vector and gene therapy CDMO services. It is a broad incumbent serving overlapping cell and gene therapy developers with substantially larger resources than CellforCure.

Emerging players

  • Center for Breakthrough Medicines: Center for Breakthrough Medicines is a US-based cell, gene, and biologics CDMO offering GMP manufacturing services. It competes for the same ATMP developers as CellforCure, particularly given CellforCure's transatlantic ambitions through the BBG partnership.
  • CellGenix: CellGenix supplies GMP-grade raw materials and also offers development and manufacturing services for cell and gene therapy. It overlaps with CellforCure in serving ATMP developers, though it is more focused on raw materials and ancillary services than full-scale cell therapy manufacturing.
  • BioElpida: BioElpida is a European cell therapy CDMO offering GMP manufacturing for cell-based therapies, including ATMPs. It is a regional, niche competitor to CellforCure serving a similar European biotech customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

CellforCure compliance and trust

Trust signal

Compliance2 records

CellforCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CellforCure leadership team

Management profile

Number of profiles

Profiles1 record

CellforCure funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CellforCure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellforCure

What does CellforCure do?

CELLforCURE is a contract development and manufacturing organization (CDMO) providing GMP-certified manufacturing of Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies. The company operates a 10,000 m² one-stop-shop facility in France with 3,000 m² of EMA-authorized, FDA-compliant GMP cleanroom space, supporting therapy developers from early-stage development through Phase III clinical trials to commercial launch.

Is CellforCure a public or private company?

CellforCure is a private company. It is classified as corporate owned and is currently operating.

When was CellforCure founded?

CellforCure was founded in 2014. It employs 101 to 250 people.

Where is CellforCure based?

CellforCure is headquartered in Paris, France, in the Europe region.

How does CellforCure make money?

One revenue line is on record: CDMO Manufacturing Services.

Who are CellforCure's main competitors?

Direct peers on record are Yposkesi and GenIbet (currently Genezen). RoslinCT is listed as a regional player. Broad incumbents are AGC Biologics, Lonza Cell & Gene Technologies, Catalent (Paragon Gene Therapy / MaSTherCell) and Thermo Fisher Scientific (Brammer Bio). Emerging players are Center for Breakthrough Medicines, CellGenix and BioElpida.

Does CellforCure have an API?

No public API is recorded for CellforCure.

What industry is CellforCure in?

CellforCure's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioProcess InternationalCDMO partnerships: Timing matters for biotech successThe article examines strategic timing considerations for biotech companies deciding when to partner with contract development and manufacturing organizations (CDMOs), using CellProthera as a case study. CellProthera built in-house manufacturing capabilities out of necessity because few CDMOs existed for cell and gene therapies before 2013, then later partnered with CDMO CELLforCURE for Phase III manufacturing and commercialization of its ProtheraCytes cell therapy. Industry perspectives are presented on the trade-offs between early CDMO partnerships and developing internal expertise, with the CEO advocating for in-house capabilities when fundraising allows.GlobeNewswireBBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)BBG Advanced Therapies and CELLforCURE announced a partnership to provide transatlantic manufacturing for advanced therapy medicinal products. The collaboration combines BBG's U.S. cGMP cleanrooms and CELLforCURE's European GMP facilities to support ATMP development and commercialization.GlobeNewswireBBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)BBG Advanced Therapies and CELLforCURE have announced a partnership aimed at supporting the development and large-scale production of Advanced Therapy Medicinal Products (ATMPs). This collaboration will enable U.S. companies to utilize CELLforCURE’s manufacturing capabilities in Europe while allowing European companies to access BBG Advanced Therapies’ production facilities in the United States. The partnership aims to enhance global CDMO capacity and facilitate faster commercialization of therapies.AabbBBG Advanced Therapies and CELLforCURE Form Transatlantic ATMP Manufacturing PartnershipBBG Advanced Therapies and CELLforCURE have formed a transatlantic partnership to support the development and large-scale production of advanced therapy medicinal products (ATMPs). This collaboration creates a network allowing U.S. companies to access European manufacturing capabilities while enabling European developers to utilize BBGAT's U.S. production capacities. The entities aim to accelerate therapy development and expand patient access to ATMPs worldwide.YahooBBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)BBG Advanced Therapies, a subsidiary of BioBridge Global based in San Antonio, Texas, has partnered with CELLforCURE, part of France-based SEQENS Group, to create a transatlantic manufacturing network for Advanced Therapy Medicinal Products (ATMPs). The collaboration enables U.S. companies to access CELLforCURE's European manufacturing capabilities while European companies can leverage BBG Advanced Therapies' U.S.-based production capacity, combining their CDMO infrastructure to support therapy developers in scaling from early-stage development through commercial launch. The partnership provides integrated GMP manufacturing space spanning both companies' facilities, including CELLforCURE's 10,000 m² one-stop-shop facility in France and BBG Advanced Therapies' 9 cGMP cleanrooms in Texas.BiobridgeglobalBBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)BBG Advanced Therapies and CELLforCURE have announced a partnership to provide transatlantic manufacturing solutions for Advanced Therapy Medicinal Products (ATMPs). This collaboration connects BBG's U.S. production capacities with CELLforCURE's European facilities, creating an integrated global CDMO network to support developers from early-stage trials through commercial launch.GlobeNewswireBBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)BBG Advanced Therapies and CELLforCURE announced a partnership to provide transatlantic manufacturing for advanced therapy medicinal products. The collaboration combines BBG's U.S. cGMP cleanrooms and CELLforCURE's European GMP facilities to support ATMP development and commercialization.GlobeNewswireBBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)BBG Advanced Therapies, a subsidiary of BioBridge Global based in San Antonio, Texas, and CELLforCURE, part of France-based SEQENS Group, announced a transatlantic partnership to provide integrated manufacturing solutions for Advanced Therapy Medicinal Products (ATMPs). The collaboration enables U.S. companies to access CELLforCURE's European manufacturing capabilities while European companies can leverage BBG Advanced Therapies' U.S. production capacity, combining 9 cGMP cleanrooms and 7 independent manufacturing lines across both facilities. The partnership aims to accelerate therapy development from concept to commercialization by providing scalable global CDMO services, with the goal of improving patient access to advanced therapies worldwide.YahooBBG Advanced Therapies and CELLforCURE Partner to Provide Transatlantic Manufacturing Solutions for Advanced Therapy Medicinal Products (ATMPs)BBG Advanced Therapies, a subsidiary of BioBridge Global based in San Antonio, Texas, has announced a partnership with CELLforCURE, part of France-based SEQENS Group, to create a transatlantic CDMO network for Advanced Therapy Medicinal Products (ATMPs). The collaboration enables U.S. companies to access CELLforCURE's European manufacturing capabilities while European companies can leverage BBG Advanced Therapies' U.S. production capacities, combining 9 cGMP cleanrooms with CELLforCURE's 7 independent manufacturing lines spanning 3,000 m² of GMP-certified space. The combined entity positions itself as a global, scalable solution to accelerate therapy developers from concept through commercialization, with both firms emphasizing regulatory compliance across FDA, EMA, and international standards.